DUAL-REGISTERED PROTOCOL // OSF PRE-REGISTERED (DOI: 10.17605/OSF.IO/VPS9D) · CLINICALTRIALS.GOV PRS IN PROGRESS · PROTOCOL ID: DS-CLIN-2026-IMMUNO-RESOLVE · PLANNED N = 10,000
IMMUNO-RESOLVE™ Registry.
De-compounding refractory autoimmunity & mucosal breakdown.
Autoimmune disease management is dominated by lifelong escalating immunosuppression without addressing gut barrier breakdown or molecular mimicry triggers. IMMUNO-RESOLVE™ is a prospective decentralized clinical registry ($N=10,000$) investigating mucosal repair kinetics and steroid-free remission trajectories under the DeepSensi Cognitive Engine. Participation in the clinical registry is 100% Free.
RESOLVE in the United States: in preparation (IRB submission in preparation, the first country to open).
Registry Strata
Three Core Autoimmune Pathology Cohorts
Refractory Inflammatory Bowel Disease (IBD)
Crohn's Disease and Ulcerative Colitis non-responsive to first-line biologics, serial tracking of fecal calprotectin, mucosal permeability, and SCFA metagenomics.
Systemic Lupus Erythematosus (SLE) & Sjogren's
Multi-system connective tissue autoimmune disorders, tracking complement consumption (C3/C4), antinuclear autoantibody subsets, and vascular endothelia.
Multiple Sclerosis & Demyelinating Disorders
Relapsing-remitting and progressive MS, tracking neurofilament light chain (NfL), blood-brain barrier permeability, and microglial inflammatory states.
From routine care, ordered by each participant's own physicians, the registry also records a metagenomic stool profile and medicine levels where applicable.
DeepSensi DCT
